Cointime

Lava Therapeutics

company

About

Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of cancer.

  • 51 - 100

Highlights

Total Funding Amount
$83M €16M
Funding Rounds
2
Investors
1

Details

Last Funding Type
Series C
Last Funding Money Raised
$83M
Industries
Biotechnology,Life Science,Medical,Medical Device
Founded date
Jan 1, 2016
Number Of Employee
51 - 100
Operating Status
Active

Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of hematological and solid cancers. Its platform creates and develops next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer as well as develop potent, safe, and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells that enable doctors to safely channel the immune system's response towards tumors.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$83M €16M
Lava Therapeutics has raised a total of $83M €16M in funding over 2 rounds. Their latest funding was raised on Sep 17, 2020 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 17, 2020 Series C $83M 1 — — Detail
May 23, 2018 Series A €16M 1 Versant Ventures — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Lava Therapeutics is funded by 1 investors. Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Versant Ventures — Series C
Cointime
เนื้อหา
บริษัท